The share issue directed to institutional investors and is subject to approval from an extraordinary general meeting
Read moreEJ FÖR DISTRIBUTION DIREKT ELLER INDIREKT, INOM ELLER TILL USA, KANADA, AUSTRALIEN, SYDAFRIKA, JAPAN, HONGKONG, SCHWEIZ, SINGAPORE ELLER…
Read moreNOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA,…
Read moreThe board of directors of Xvivo Perfusion AB (publ) (“Xvivo” or the “Company”) (NASDAQ OMX First North: XVIVO) has, pursuant to an authorization from the annual general meeting held on April 29, 2014, resolved to issue 1,950,000 new shares in Xvivo through a private placement directed to a group of qualified Swedish and international investors (the “Private Placement”). The Private Placement was announced on June 25, 2014 and was fully subscribed.
Read moreXvivo Perfusion AB:s (publ) (“Xvivo” eller “Bolaget”) (NASDAQ OMX First North: XVIVO) styrelse har, med stöd av årsstämmans bemyndigande från den 29 april 2014, beslutat att emittera totalt 1 950 000 nya aktier i Xvivo med avvikelse från aktieägarnas företrädesrätt till en grupp svenska och internationella kvalificerade investerare (“Nyemissionen”). Nyemissionen aviserades den 25 juni 2014 och är nu fulltecknad.
Read more
